Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule
View Patent ↗The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R 1 —XZSZ N —XZX—R 2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
1. A vaccine comprising:
an HBV antigen;
a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6); and
a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN), wherein the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 21).
2. The vaccine of claim 1 , further comprising an Al(OH) 3 adjuvant.
3. The vaccine of claim 1 , wherein the HBV antigen is Hepatitis B surface antigen (HBsAg).
4. The vaccine of claim 1 , further comprising a polycationic peptide.
5. The vaccine of claim 1 , further comprising an oligodeoxynucleotide containing a CpG-motif.
6. The vaccine of claim 1 , further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.
7. A method of improving protective efficacy of a vaccine against an HBV infection comprising:
obtaining a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6) and an I-ODN of claim 1 , wherein the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 21); and
administering the peptide and the I-ODN with a vaccine against an HBV infection to a subject;
wherein efficacy of the vaccine against an HBV infection is improved in the subject.
8. A method of improving an antigen-specific type 1 response of a vaccine against an HBV infection and preserving or increasing a type 2 response of said vaccine comprising:
obtaining a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6) and an I-ODN of claim 1 , wherein the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 21); and
administering the peptide and the I-ODN with a vaccine against an HBV infection to a subject;
wherein the antigen-specific type 1 response to the vaccine against an HBV infection is improved in the subject and the type 2 response to the vaccine is preserved or increased in the subject.
9. A immunogenic composition comprising:
an HCV antigen,
a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6), and
a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN), wherein the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 21).
10. The immunogenic composition of claim 9 , further comprising an Al(OH) 3 adjuvant.
11. The immunogenic composition of claim 9 , wherein the HCV antigen is a peptide.
12. The immunogenic composition of claim 9 , further comprising a polycationic peptide.
13. The immunogenic composition of claim 9 , further comprising an oligodeoxynucleotide containing a CpG-motif.
14. The immunogenic composition of claim 9 , further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.
15. A method of improving efficacy of a immunogenic composition against an HCV infection comprising:
obtaining a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6) and an I-ODN of claim 9 , wherein the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 21); and
administering the peptide and the I-ODN with a immunogenic composition against an HCV infection to a subject;
wherein efficacy of the immunogenic composition against HCV infection is improved in the subject.
16. A method of improving an antigen-specific type 1 response of a immunogenic composition against an HCV infection and preserving or increasing a type 2 response of said immunogenic composition comprising:
obtaining a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6) and an I-ODN of claim 9 , wherein the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 21); and
administering the peptide and the I-ODN with a immunogenic composition against an HCV infection to a subject;
wherein the antigen-specific type 1 response to the immunogenic composition against an HCV infection is improved in the subject and the type 2 response to the immunogenic composition is preserved or increased in the subject.
17. The method of claim 8 or 16 , wherein the antigen-specific type 1 response is further defined as an IgG2-antibody response or IFN-gamma response.
18. The method of claim 8 or 16 , where in the type 2 response is further defined as an IgG1-antibody response or interleukin-4 (IL-4) response.